Get alerts:The company generated $67 million in U.S. net product sales during the quarter, up 14% from the prior-year period. TAVALISSE recorded quarterly net product sales of $47.4 million, a year-over-year increase of 18%. Grade 3 or higher treatment-emergent adverse events occurred in 23% of vepdegestrant patients and 18% of fulvestrant patients. Rigel said 3% of vepdegestrant patients discontinued treatment because of adverse events and 2% required dose reductions. About Rigel Pharmaceuticals (NASDAQ:RIGL)Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California.